Healthcare [ 7/13 ] | Biotechnology [ 82/163 ]
NASDAQ | Common Stock
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States.
It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.
The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 13, 24 | -0.83 Decreased by -23.88% | -0.76 Decreased by -9.21% |
| Mar 25, 24 | -0.74 Decreased by -21.31% | -0.71 Decreased by -4.23% |
| Nov 13, 23 | -0.71 Decreased by -26.79% | -0.69 Decreased by -2.90% |
| Aug 14, 23 | -0.76 Decreased by -55.10% | -0.70 Decreased by -8.57% |
| May 15, 23 | -0.67 Decreased by -48.89% | -0.60 Decreased by -11.67% |
| Mar 29, 23 | -0.61 Decreased by -74.29% | -0.62 Increased by +1.61% |
| Nov 14, 22 | -0.56 Decreased by -115.38% | -0.50 Decreased by -12.00% |
| Aug 15, 22 | -0.49 Increased by +97.94% | -0.45 Decreased by -8.89% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 0.00 Decreased by N/A% | -23.19 M Decreased by -50.55% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 136.00 K Increased by +N/A% | -20.41 M Decreased by -35.89% | Decreased by -15.01 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -19.56 M Decreased by -50.21% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -19.02 M Decreased by -61.68% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -15.40 M Decreased by -42.59% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -15.02 M Decreased by -82.68% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -13.02 M Decreased by -110.61% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -11.77 M Decreased by -103.76% | Decreased by N/A% Decreased by N/A% |